Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml

Lucarelli, Giuseppe; Fanelli, Margherita; Larocca, Angela Maria Vittoria; Germinario, Cinzia Annatea; Rutigliano, Monica; Vavallo, Antonio; Selvaggi, Francesco Paolo; Bettocchi, Carlo; Battaglia, Michele; Ditonno, Pasquale

doi:10.1002/pros.22514

Cited by 86 publications

(87 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interest in this molecule was increased in 2009 when Sreekumar and colleagues (19) published their study regarding metabolomic profiles of urine obtained from CaP patients. Even though the linkage of sarcosine with prostate carcinoma development was reported (20,21) as well as its potential in the diagnosis of early-stage tumors (4,22), its use as a marker is still under discussion (23). Hence, it is necessary to study the functions of sarcosine and other amino acids, acting as the intermediate products of metabolism influenced by tumor growth.…”

Section: Introductionmentioning

confidence: 99%

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

et al. 2014

View full text Add to dashboard Cite

Abstract.Recently, interest in the identification of non-invasive markers for prostate carcinoma detectable in the urine of patients has increased. In this study, we monitored the abundance of potential non-invasive markers of prostate carcinoma such as amino acid sarcosine, involved in the metabolism of amino acids and methylation processes, ongoing during the progression of prostate carcinoma. In addition, other potential prostate tumor markers were studied. The most significant markers, prostate-specific antigen (PSA) and free PSA (fPSA), already used in clinical diagnosis, were analyzed using an immunoenzymometric assay. Whole amino acid profiles were also determined to evaluate the status of amino acids in patient urine samples and to elucidate the possibility of their utilization for prostate carcinoma diagnosis. To obtain the maximum amount of information, the biochemical parameters were determined using various spectrophotometric methods. All results were subjected to statistical processing for revealing different correlations between the studied parameters. We observed alterations in most of the analyzed substances. Based on the results obtained, we concluded that the specificity of prostate carcinoma diagnosis could be improved by determination of common urine metabolites, since we compiled a set of tests, including the analysis of sarcosine, proline, PSA and uric acid in the urine. These metabolites were not observed in the urine obtained from healthy subjects, while their levels were elevated in all patients suffering from prostate carcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Sarcosine was suggested as a candidate marker for prostate cancer (PCa) [77]; however, its effectiveness has been debated [78,79]. Validations in another sample group indicated that serum sarcosine is more sensitive than PSA among patients with PSA <4 ng/ml [78].…”

Section: Genitourinary Cancermentioning

confidence: 99%

“…Validations in another sample group indicated that serum sarcosine is more sensitive than PSA among patients with PSA <4 ng/ml [78]. Plasma-free fatty acid profiles could be influenced by different pathological states, and multivariate analysis of plasma-free fatty acids could be used as markers to differentiate malignancy (e.g., PCa) from controls [80].…”

Section: Genitourinary Cancermentioning

confidence: 99%

“…Many reported tumor markers could be used as a basis for molecular classification. Sarcosine was reported to classify low-and high-grade PCa [78]. Wei and colleagues evaluated the inhibitory effects of two antineoplastic agents (salvianolic acid B and breviscapine) on oral carcinogenesis using a GC-TOF platform [98].…”

Section: Personalized Treatment Of Tumor Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics for tumor marker discovery and identification based on chromatography–mass spectrometry

Yin

2013

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Early detection is the most effective way to improve the clinical outcome of malignancies. Although some tumor markers are now widely used in the clinic, their sensitivity and specificity are still not satisfactory. Thus, there is an urgent requirement for the discovery of new tumor markers. By measuring holistic endogenous metabolites, metabolomics can be used for delineating metabolic networks and discovering metabolic markers. Chromatography-mass spectrometry is the most widely used tool for metabolomics and has shown great potential for biomarker screening. In this review, the authors summarize: recent advances in the protocols and methodologies of chromatography-mass spectrometry-based metabolomics in the discovery of tumor markers; recently identified tumor metabolic markers for primary liver cancer, gynecologic cancer and genitourinary cancer and their applications; and commonly encountered problems in the translational research of metabolic markers.

show abstract

“…However, the metabolomic approach to this purpose could be relatively easy if we are able to identify one or a few compounds typical of the disease and absent in a healthy status (e.g., the sarcosine in prostate cancer [13]), but could be difficult when these compounds are unknown.…”

mentioning

confidence: 99%

Breath test: a new diagnostic tool for colorectal cancer?

2013

View full text Add to dashboard Cite

Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml

Cited by 86 publications

References 47 publications

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

Metabolomics for tumor marker discovery and identification based on chromatography–mass spectrometry

Breath test: a new diagnostic tool for colorectal cancer?

Contact Info

Product

Resources

About